{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089074","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.518220+00:00","generated_at":"2026-06-11T23:14:07.235732+00:00","sec_items":["5.07","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MedTech Acquisition shareholders approve TriSalus merger; $9.4M redeemed","bullets":["All 14 proposals approved by >99% of votes cast at August 8 special meeting.","Holders of 890,499 Class A shares elected redemption for ~$9.42M ($10.58/share) from trust.","Business combination with TriSalus expected to close subject to conditions.","Combined company securities to trade on Nasdaq under symbols TLSI (common) and TLSIW (warrants).","Adjournment proposal not presented due to sufficient votes for all proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089074","json":"https://secwatch.observer/filing/0001104659-23-089074.json","markdown":"https://secwatch.observer/filing/0001104659-23-089074.md","text":"https://secwatch.observer/filing/0001104659-23-089074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/tm2323269d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:14:07.235732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fb6dbc196c8fc1cf9a2b0884230d92493617ed2","claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3A at the 2023-08-08 meeting.","evidence_excerpt":"3A. Governance Proposal 3A : For Against Abstain 7,134,005 20,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"201da31ad3c883a825a6509fcc3e96f0360d5fb1","claim":"TriSalus Life Sciences, Inc. shareholders approved The Charter Approval Proposal at the 2023-08-08 meeting.","evidence_excerpt":"2. The Charter Approval Proposal : i. Class A Common Stock For Against Abstain 7,135,004 19,016 0 ii. Class B Common Stock For Against Abstain 1 0 0 iii. Total Common Stock For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"2d31a9f4a41f9be9a220fbe5766cf5faf1537cbc","claim":"TriSalus Life Sciences, Inc. shareholders approved The Nasdaq Proposal at the 2023-08-08 meeting.","evidence_excerpt":"6. The Nasdaq Proposal : For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"3aca8baf295a208491d07a08751bcb2261c1c989","claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3D at the 2023-08-08 meeting.","evidence_excerpt":"3D. Governance Proposal 3D : For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"4116f6fee81f565e0ec6ecea072e9d43023739e3","claim":"TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal B at the 2023-08-08 meeting.","evidence_excerpt":"7B. Director Nomination Proposal B : i. David J. Matlin For Withheld 7,135,005 19,016","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"590490201c57accfe5e6ec1f1d9383c7488bd4e4","claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3C at the 2023-08-08 meeting.","evidence_excerpt":"3C. Governance Proposal 3C : For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"6ea0ce5ec4ab28cbd8ba9922180efe8f156a9fa5","claim":"TriSalus Life Sciences, Inc. shareholders approved The Business Combination Proposal at the 2023-08-08 meeting.","evidence_excerpt":"1. The Business Combination Proposal : For Against Abstain 7,135,003 19,016 2","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"7538fd18f9ef66403dedbb78db9e53f0a1e2ac4b","claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3B at the 2023-08-08 meeting.","evidence_excerpt":"3B. Governance Proposal 3B : For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"775a6d64442b712463357e08ac0503c9def22962","claim":"TriSalus Life Sciences, Inc. shareholders approved The Stock Plan Proposal at the 2023-08-08 meeting.","evidence_excerpt":"4. The Stock Plan Proposal : For Against Abstain 7,135,000 19,021 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"81a4c43a4cba1d3209c6fd171cd4ab0a1e77857e","claim":"TriSalus Life Sciences, Inc. shareholders approved Governance Proposal 3E at the 2023-08-08 meeting.","evidence_excerpt":"3E. Governance Proposal 3E : For Against Abstain 7,135,005 19,016 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"846dfb29e7314362481647c233b6ec2abb45437e","claim":"TriSalus Life Sciences, Inc. shareholders approved The ESPP Proposal at the 2023-08-08 meeting.","evidence_excerpt":"5. The ESPP Proposal : For Against Abstain 7,135,000 19,021 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"},{"claim_id":"a5cc85da8756df765279c79efd1d2408bc272e78","claim":"TriSalus Life Sciences, Inc. shareholders approved Director Nomination Proposal A at the 2023-08-08 meeting.","evidence_excerpt":"7A. Director Nomination Proposal A : i. Anil Singhal For Withheld 7,135,005 19,016","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923089074/0001104659-23-089074-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}